Related Experiment Videos

Sacubitril/valsartan plus dapagliflozin improves cardiac function and reduces MACE and rehospitalization in hFrEF: a

Nimin Lu1, Jinzhao Li2, Tianzhu Li3

  • 1Cardiac Rehabilitation Center, The First Affiliated Hospital of Jinzhou Medical University Jinzhou 121001, Liaoning, China.

American Journal of Translational Research
|August 22, 2026
PubMed

Insights

Adding dapagliflozin to sacubitril/valsartan significantly improved cardiac function and exercise tolerance in heart failure with reduced ejection fraction (HFrEF) patients. This combination therapy reduced major adverse cardiovascular events (MACE) and hospital readmissions without increasing adverse reactions.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Heart failure with reduced ejection fraction (HFrEF) remains a significant cause of morbidity and mortality.
  • Current therapies aim to improve cardiac function and reduce adverse events.
  • Novel therapeutic combinations are being investigated to enhance treatment efficacy.

Purpose of the Study:

  • To assess the efficacy and safety of combining sacubitril/valsartan with dapagliflozin in HFrEF patients.
  • To compare the outcomes of this combination therapy against sacubitril/valsartan monotherapy.

Main Methods:

  • A retrospective study involving 400 HFrEF patients, divided into a control group (sacubitril/valsartan) and an observation group (sacubitril/valsartan + dapagliflozin).
  • Patients were treated for 6 months, with assessments including cardiac function (LVEF, LVEDD, LVESD), NT-proBNP levels, 6-minute walk test (6MWT), major adverse cardiovascular events (MACE), readmission rates, and adverse reactions.

Main Results:

  • The combination group showed a significantly greater improvement in left ventricular ejection fraction (LVEF) compared to the control group.
  • Reductions in left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and NT-proBNP were more pronounced in the combination group.
  • The combination therapy resulted in significantly lower readmission rates and MACE, with no significant increase in adverse reactions.

Conclusions:

  • Sacubitril/valsartan combined with dapagliflozin offers superior clinical benefits in HFrEF patients compared to sacubitril/valsartan alone.
  • This combination improves cardiac function, enhances exercise capacity, and reduces cardiovascular events and hospitalizations.
  • The addition of dapagliflozin to sacubitril/valsartan is a safe and effective strategy for managing HFrEF.
Abstract

Keywords:
Heart failureadverse reactionsclinical efficacydapagliflozinsacubitril valsartan

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...